Skip to content
Disclosery

MWG Management Ltd.

Follow

13F filer, CIK 1845151, Washington, DC

MWG Management Ltd. reported $51,899,051 across 3 holdings for the quarter ended 2025-06-30, in a 13F-HR filed 2025-08-14.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000950123-25-008264

Period
2025-06-30
Reported value
$51.9M
Holdings
3
Top 10 weight
100%
New
0
Sold out
0

Largest buys vs the previous quarter

None.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
LYELL IMMUNOPHARMA INCreduced-19,154,216-$169M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2025

Share positions as resolved from 13F-HR 0000950123-25-008264, largest first. % of portfolio is the value over $51,899,051, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
BEAMBEAM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: 2,346,934 shares; 2024Q1: 2,346,934 shares; 2024Q2: 2,266,934 shares; 2024Q3: 2,266,934 shares; 2024Q4: 2,266,934 shares; 2025Q1: 2,266,934 shares; 2025Q2: 2,266,934 shares 2,266,934$38.6M74.3%0Timeline
LYELL IMMUNOPHARMA INCLYELL IMMUNOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: 20,162,332 shares; 2024Q1: 20,162,332 shares; 2024Q2: 20,162,332 shares; 2024Q3: 20,162,332 shares; 2024Q4: 20,162,332 shares; 2025Q1: 20,162,332 shares; 2025Q2: 1,008,116 shares 1,008,116$8.91M17.17%-19,154,216
PRMEPRIME MEDICINE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: 1,792,210 shares; 2024Q1: 1,792,210 shares; 2024Q2: 1,792,210 shares; 2024Q3: 1,792,210 shares; 2024Q4: 1,792,210 shares; 2025Q1: 1,792,210 shares; 2025Q2: 1,792,210 shares 1,792,210$4.43M8.53%0Timeline

How Q2 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0000950123-25-008264 base2025-08-14acceptance time not in the bulk data set